Prognosis of Small Cell Lung Cancer with Idiopathic Pulmonary Fibrosis: Assessment according to GAP Stage

Table 5

Chemotherapy regimens in this study.

	Total	GAP stage I	GAP stage II/III
Chemotherapy (Total=30, GAP stage I=21, GAP stage II/III =9)
EC	11 (36.7)	7 (33.3)	4 (44.4)
EP	13 (43.3)	12 (57.1)	1 (11.1)
IP	4 (13.3)	1 (4.8)	3 (33.3)
BP	2 (6.7)	1 (4.8)	1 (11.1)
Concurrent chemoradiotherapy (Total=21, GAP stage I=16, GAP stage II/III=5)
EC	8 (38.1)	6 (37.5)	2 (40.0)
EP	10 (47.6)	8 (50.0)	2 (40.0)
IP	3 (14.3)	2 (12.5)	1 (20.0)

Values are presented as No. (%).
Abbreviations: BP, belotecan+cisplatin; EC, etoposide+carboplatin; EP, etoposide+cisplatin; IP, irinotecan+cisplatin.